Study: HAND2-AS1's Role in Blood Clotting and Disease (G79804)

Target Name: HAND2-AS1

NCBI ID: G79804

HAND2-AS1

Other Name(s): DEIN | UPH | HAND2 antisense RNA 1 | NBLA00301 | HAND2 antisense RNA 1, transcript variant 1

Study: HAND2-AS1's Role in Blood Clotting and Disease

Hand2-AS1 (DEIN), a protein found in human platelets, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function have made it an attractive target for researchers to study, and its potential as a drug has piqued the interest of pharmaceutical companies.

The protein HAND2-AS1 is a key component of the blood platelet, which is responsible for blood clotting. It is made up of two subunits, alpha-IIb尾3 (HAND2) and alpha-IX (AS1), and is expressed in high levels in the body's immune cells, particularly natural killer cells and T cells. Its function is to regulate the interactions between platelet components, allowing them to stick together and form blood clots when needed.

HAND2-AS1 has been shown to play a crucial role in the regulation of platelet function and interactions. It has been shown to interact with several other proteins, including GPI-anchored molecules, such as ITGA2, CD73, and PDCD1, as well as with several intracellular signaling pathways, including the TGF-β pathway.

HAND2-AS1 has also been shown to be involved in several diseases and disorders, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that high levels of HAND2-AS1 are associated with an increased risk of developing multiple sclerosis, a neurodegenerative disorder that causes muscle weakness and numbness. Additionally, HAND2-AS1 has been shown to be involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

Furthermore, HAND2-AS1 has also been shown to be a potential drug target for cancer. Studies have shown that HAND2-AS1 is often overexpressed in cancer cells, and that inhibiting its function may be an effective way to treat cancer. Additionally, HAND2-AS1 is often overexpressed in cancer cells, and that inhibiting its function may be an effective way to treat cancer. AS1 has been shown to be involved in the development of several types of cancer, including breast, lung, and ovarian cancer.

In addition to its potential as a drug target, HAND2-AS1 has also been shown to be a potential biomarker for several diseases. Its expression has been shown to be associated with several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Additionally, HAND2-AS1 has been shown to have a different expression level in different tissues and diseases, which could be used as a potential biomarker for several diseases.

Overall, HAND2-AS1 is a protein that has a significant impact on the body's immune system and platelet function. Its unique structure and function make it an attractive target for research into the development of new drugs and treatments for a variety of diseases. As further research is conducted, it is likely that the potential uses for HAND2-AS1 will continue to grow.

Protein Name: HAND2 Antisense RNA 1

The "HAND2-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HAND2-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets